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Abstract
Background: Human rights approaches to manage HIV and efforts to decriminalize HIV exposure/transmission
globally offer hope to persons living with HIV (PLWH). However, among vulnerable populations of PLWH,
substantial human rights and structural challenges (disadvantage and injustice that results from everyday practices
of a well-intentioned liberal society) must be addressed. These challenges span all ecosocial context levels and in
North America (Canada and the United States) can include prosecution for HIV nondisclosure and HIV exposure/
transmission. Our aims were to: 1) Determine if there were associations between the social structural factor of
criminalization of HIV exposure/transmission, the individual factor of perceived social capital (resources to support
one’s life chances and overcome life’s challenges), and HIV antiretroviral therapy (ART) adherence among PLWH and
2) describe the nature of associations between the social structural factor of criminalization of HIV exposure/
transmission, the individual factor of perceived social capital, and HIV ART adherence among PLWH.
Methods: We used ecosocial theory and social epidemiology to guide our study. HIV related criminal law data
were obtained from published literature. Perceived social capital and HIV ART adherence data were collected from
adult PLWH. Correlation and logistic regression were used to identify and characterize observed associations.
Results: Among a sample of adult PLWH (n = 1873), significant positive associations were observed between
perceived social capital, HIV disclosure required by law, and self-reported HIV ART adherence. We observed that
PLWH who have higher levels of perceived social capital and who live in areas where HIV disclosure is required by
law reported better average adherence. In contrast, PLWH who live in areas where HIV transmission/exposure is a
crime reported lower 30-day medication adherence. Among our North American participants, being of older age, of
White or Hispanic ancestry, and having higher perceived social capital, were significant predictors of better HIV ART
adherence.
Conclusions: Treatment approaches offer clear advantages in controlling HIV and reducing HIV transmission at the
population level. These advantages, however, will have limited benefit for adherence to treatments without also
addressing the social and structural challenges that allow HIV to continue to spread among society’s most
vulnerable populations.
Keywords: Ecosocial theory, HIV/AIDS, HIV-related prosecution, Jurisprudence, Sexual minority, Vulnerable
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Human rights approaches to manage HIV and efforts to
decriminalize HIV exposure/transmission globally offer
hope to persons living with HIV (PLWH). However, among
vulnerable populations of PLWH globally, substantial hu-
man rights and structural challenges still exist and must be
addressed [1-4]. These challenges span all ecosocial levels of
a PLWH’s context (i.e., individual, interpersonal, social and
structural levels). The ecosocial structural level includes so-
cial structures (e.g., the legal system, social class) that may
influence health [5-8]. In North America (Canada and the
United States) the legal context of HIV may include pros-
ecution for nondisclosure of an HIV positive serostatus to
sexual partners, exposing others to HIV, and HIV transmis-
sion [9-17]. The criminalization of HIV exposure/transmis-
sion and prosecutions for HIV exposure include cases
involving transmission of the virus and cases of HIV
nondisclosure of an HIV positive serostatus, with or without
HIV transmission. In a world that is striving to end the
AIDS epidemic [18], understanding the complex challenge
that prosecution of persons for HIV exposure creates for so-
cieties is essential.
Criminalization of HIV exposure/transmission is an
ecosocial structural process that is embodied in “the disad-
vantage and injustice some people suffer… because of the
everyday practices of a well-intentioned liberal society”
[19,20]. In many communities, the over-use of criminal law
as an HIV prevention strategy has contributed to stigma
and discrimination against PLWH [14,21]. This HIV preven-
tion strategy may be problematic in communities that have
adopted the structural HIV prevention intervention of treat-
ment as prevention and communities where test and treat
programs are being scaled up [22,23]. Each of these struc-
tural HIV prevention intervention strategies are being used
in North America. As indicated by UNAIDS [24] a review
of existing laws that criminalize HIV exposure, HIV trans-
mission, and nondisclosure of HIV positive serostatus can
identify those laws and legal precedents that are vague or
open to misinterpretation, and that lead to discrimination.
However such a review is missing from the current scientific
literature. The purpose of this study was to better under-
stand the ecosocial and legal contexts in which PLWH live
in North America. To that end, we examined the influence
of the criminalization of HIV exposure/transmission,
reported prosecutions for HIV exposure/transmission and
perceived social capital on HIV ART adherence among
PLWH in Canada and the United States. We used ecosocial
theory and social epidemiological methods to guide our
research.
Background and significance
HIV-related criminal law: effective policy or tool of
oppression?
Structural level challenges are barriers to an individual’s
HIV-related health promoting behavior and include
economic, social, policy, and organizational aspects of
the environmental context [25]. The criminalization of
HIV exposure/transmission and the risk of prosecution
based on HIV status is a controversial structural chal-
lenge faced by many PLWH globally [14,26-28].
Criminalization of HIV exposure/transmission and pros-
ecution for HIV exposure takes on many forms includ-
ing enhancements (e.g., the application of additional or
more severe criminal penalties) during sentencing for
other crimes when HIV is a factor in the case; court de-
cisions that consider HIV a “deadly weapon,” resulting in
PLWH being prosecuted for spitting; and laws that
criminalize potential HIV transmission, without evidence
of intent [14,26-28]. These prosecutions occur even
when there is evidence that the PLWH has an undetect-
able HIV viral load and practices safer sex by using a
condom, rendering HIV transmission highly unlikely
[14,26-28]. Multinational and non-governmental organi-
zations have highlighted the challenges that the
criminalization of HIV exposure/transmission pose for
effective HIV prevention, care, treatment, and manage-
ment [26,29]. Substantial evidence suggests that the
criminalization of HIV exposure/transmission has lim-
ited benefit for population health and may adversely
affect individual behavior [9-11,13,14,16]. Prosecutions
for HIV exposure have occurred in Canada and the
United States since the beginning of the epidemic and
are increasing in some jurisdictions within the two coun-
tries [12,15,27]. The current trends in prosecutions for
HIV exposure and nondisclosure may create challenges
for managing HIV in a way that respects human rights
and dignity for all members of society. Further research
is needed to guide policy-makers, courts and legislative
bodies about how to interpret the scientific knowledge
in an era of HIV as a manageable chronic illness, in con-
trast to earlier eras when HIV was perceived to be a
death sentence and public health menace. In jurisdic-
tions where prosecution for HIV exposure is possible,
the extent to which prosecutions affect health promoting
behaviors among PLWH is not evident and has not been
studied. Understanding the effects that the threat of
prosecution for HIV exposure has on an individual’s
health promoting behaviors (e.g., HIV ART adherence,
seeking HIV testing and treatment, serostatus disclosure)
is critically important to efforts to bring about an end to
the HIV epidemic.
Social capital: collective resources and credits to achieve
health
When PLWH navigate the structural challenges of their
ecosocial context environment, social capital may be an
essential element for the attainment of optimal health.
Social capital is the “aggregate of potential resources
which are linked to possession of a durable network of
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more or less institutionalized relationships of mutual ac-
quaintance or recognition” [30], p.248; [31]. Social cap-
ital provides members with “credit(s)” to be used in the
larger social world to achieve their interests and engage
in activities and services to achieve optimal health
[31-37]. In short, social capital is the resources to sup-
port one’s life chances and overcome life’s challenges
[38]. Social capital defined in this way may protect
PLWH from many of the structural challenges they en-
counter in society, because of a collective advantage.
This was the case during the first decades of HIV when
gay men and other minority groups rallied together to
empower governments to respond to the HIV epidemics
in North America and Western Europe [39,40]. The
resulting work led to the development and approval of
accessible HIV antiretroviral treatment and public insur-
ance programs to cover the cost of these life-saving
medications and related health care. However, mirroring
global societal trends, such efforts have recently been
diffuse and the social capital that was previously devel-
oped among these populations may have diminished
[41].
Racism, sexism and homophobia
The social structural phenomena of racism, sexism, and
homophobia may be factors in the criminalization of
HIV in some communities. These factors may be evident
in the numbers of ancestral (racial/ethnic) or other mi-
nority persons who are prosecuted for HIV-related
crimes or for sentencing enhancements when HIV is a
factor in criminal proceedings [12,15]. The structural
factors of racism and sexism have been documented as
determinants of health and contribute to adverse health
outcomes among PLWH globally [42,43]. Racism and
sexism are forms of domination that result in oppressive
power imbalances in societies [44]. Racial and sexual mi-
norities in Canada and the United States have been dis-
proportionately affected by the HIV epidemic and racial
minorities experience higher rates of criminal prosecu-
tions than other members of these societies. Sexism and
homophobia have been attributed to the gender hier-
archy in society [45]. Homophobia has been termed a
weapon of sexism [46] and has been documented as a
factor influencing the health and health outcomes of
PLWH [47]. The criminalization of HIV and homopho-
bia in Canada and the United States may adversely affect
HIV prevention and treatment efforts among racial and
sexual minority groups [9-12,14,15,26,48,49].
Currently, the global awareness about groups of per-
sons most at risk for HIV is changing. This change in
awareness is brought about by a recognition that groups
who have been at risk for HIV transmission since the be-
ginning of the epidemic remain at risk and continue to
be disproportionately affected by HIV. These groups
include gay and other men who have sex with men
(MSM) and women of color. Although gay men in North
America, Europe and Oceania were empowered in the
early days of the epidemic, HIV epidemics among MSM
in these regions and in most countries continue to ex-
pand [50]. HIV prevalence among MSM is substantially
higher than the general male adult population globally
[50]. The structural challenges in western nations that
influence the health outcomes of MSM are substantially
different from those in developing nations, but have pro-
found influences on health outcomes. These structural
challenges include heteronormativity and racial inequal-
ity [51,52]. In the United States, there is substantial
evidence that Black MSM are more likely to be HIV-
infected than white MSM [53]. This indicates the likeli-
hood of intersecting vulnerabilities among MSM who
are both sexual minorities and members of ancestral (ra-
cial/ethnic) minority groups [51]. In Canada the likeli-
hood of acquiring HIV-infection is similar for black
MSM and white MSM [53]. Legal scholars have sug-
gested that “the gay community is an important source
of values that protect against criminalization” of HIV
[15]. Mutual responsibility for the prevention of HIV
transmission through safer sex practices has been a hall-
mark of gay communities’ responses to HIV [15].
Mykhalovskiy & Betteridge [15] warn of a potential chal-
lenge for the legal context of HIV if there is erosion of
the valuing of mutual responsibility for the prevention of
the sexual transmission of HIV in a community with
high HIV prevalence. They were concerned about the
potential to overwhelm legal systems with new prosecu-
tions for HIV nondisclosure if there is a change in valu-
ing mutual responsibility among members of the gay
community. Research is needed to inform health policy
makers and guide intervention development to address
the structural challenges that influence HIV-related
health outcomes among gay men and other MSM.
Theoretical framework
Ecosocial theory [6] and social epidemiology methods
were used to better understand the relationships be-
tween the criminalization of HIV at the structural level,
individuals’ perceived social capital, and the health pro-
moting behavior of HIV antiretroviral adherence among
PLWH (Figure 1). Ecosocial theory equally values all
stakeholder (e.g., PLWH, social network members,
health care providers, public health and other govern-
ment officials) perspectives and advocates for studying
the influences of structural level policies (e.g.,
criminalization of HIV), both codified and enacted,
across all levels of the ecosocial environment (e.g., indi-
vidual, interpersonal, social and structural levels) and is
mindful of the simultaneous and reciprocal effects across
those levels [6,54]. Additionally, ecosocial theory is
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interested in exploring the pathways and power dynam-
ics that contribute to health outcomes. The core con-
structs of ecosocial theory are embodiment; pathways of
embodiment; cumulative interplay of exposure, suscepti-
bility and resistance; and accountability and agency.
Ecosocial theory seeks to integrate social and biological
reasoning with a dynamic, historical and ecological per-
spective to understand population health phenomena
[5-8,55]. It is compatible with the structural level con-
cepts of health as a human right and the social determi-
nants of health that influence health outcomes for all
members of society, including PLWH [1,3,43,56]. Fur-
thermore, ecosocial theory provides a mechanism for
better understanding the intrinsic relationships that
shape population health [5-8]. Krieger [7] described four
intrinsic relationships to characterize populations: ge-
nealogical (relationships based on biological descent), in-
ternal and economical (relationships essential to daily
activities to maintain life), external and ecological (rela-
tionships between populations and the environs they
coinhabit), and teleological (conscious purpose–span-
ning from mutual benefit to exploitation) [7]. Social
capital is shaped by genealogical relationships and en-
compasses internal and economical and external and
ecological relationships. Building on these ecosocial the-
oretical foundations, we proposed that the structural
process of criminalization of HIV exposure/transmission
and individually perceived social capital influence ART
adherence behaviors among PLWH. We considered HIV
ART adherence over a 30 day period as a proxy measure
for individual level health promotion engagement. This
proxy measure is assumed to provide evidence of an in-
dividual’s ability to engage with the health care system
(e.g., seek medical treatment), obtain necessary health
care services (e.g., obtain clinic care and pharmacy ser-
vices), and practice health promoting self-care behaviors
(e.g., obtain prescriptions and take medications).
Research aims
In keeping with our ecosocial theoretical framework, we
had two primary research aims. Our aims were to: 1)
Determine if there were associations between the social
structural factor of criminalization of HIV, the individual
factor of perceived social capital, and HIV ART adher-
ence among an international sample of PLWH and 2)
describe the nature of associations between the social
structural factor of criminalization of HIV, the individual
factor of perceived social capital, and HIV ART adher-
ence among a North American sample of PLWH.
Methods
The use of ecosocial theory and social epidemiology to
guide our analysis provided the advantage of allowing in-
clusion of publically available structural level data about
the legal context of HIV to be combined with our indi-
vidual level survey data about HIV ART adherence, per-
ceived social capital, and demographic characteristics
among PLWH. Ecosocial theory offered contextual guid-
ance to understand the simultaneous response across
and between societal levels in environments where
PLWH live [6,54]. Social epidemiological methods were
used because they offer the advantage of including mul-
tiple data sources, not just traditional health and health
service data to gain a contextualized understanding of
what was observed [54,57].
Ecosocial environmental data studied
This study used structural level data obtained from publi-
cally available data sources and individual level survey data
obtained from the International Nursing Network for HIV
Research Study V [37,58,59]. The International Nursing Net-
work for HIV Research is an interprofessional network of re-
searchers with extensive experience conducting clinical
research with PLWH globally [60]. Study sites were selected
by convenience, with principal investigators from among
Figure 1 The ecosocial context of HIV-related criminal laws, social capital, and HIV antiretroviral adherence in North America.
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members of the International Nursing Network for HIV Re-
search choosing to participate in the main study.
Survey design and sampling strategy
This study is a sub-analysis of an international nursing
collaborative study with data obtained from infectious
disease clinics and AIDS service organizations from 21
sites in five countries. Survey data analyzed for this
study are limited to our study sites in Canada and the
United States, including Puerto Rico. The study protocol
was approved by the ethics board at the coordinating
site at the University of California, San Francisco (UCSF)
and University of British Columbia, Behavioural Re-
search Ethics Board; University of Washington Human
Subjects Division; Northeast Ohio: University Hospitals/
Case Medical Center Internal Review Board; University
of Puerto Rico, Institutional Review Board; Institutional
Review Board in the Texas A&M University-Corpus
Christi Compliance Office; Rutgers Institutional Review
Board for the Protection of Human Subjects; Institu-
tional Review Board of the North Jersey Community
Research Initiative; University of North Carolina
Wilmington, Office of Research Services, Institutional
Review Board; Partners Internal Review Board, Massa-
chusetts General Hospital; Duke University Institutional
Review Board; Hunter College (City University of New
York [CUNY]) Human Research Protection Program
(HRPP) Office; and the University of Hawaii at Manoa
Committee on Human Studies. The parent study was
also approved at sites in China, Namibia, and Thailand
by the Shanghai Public Health Clinic Center Institution
Review Board; Ethics Committee of the Ministry of
Health and Social Services, Namibia; Ethics Committee
of the University of Namibia; and The Ethical Commit-
tee of Lerdsin Hospital, Governmental Hospital,
Bangkok, Thailand. The demographic characteristics and
methods of this study have been previously published
[37,58,61]. Selected demographic, survey, and environ-
mental contextual data relevant to the aims of this study
are presented.
Study variables and data sources
Data obtained for our structural indicator, the
criminalization of HIV exposure/transmission, were
obtained from various publically available data sources
or by conducting Internet searches to obtain the relevant
information for analysis. These datasets are described in
detail below. We used multiple indicators to assess the
effects of the criminalization of HIV exposure/transmis-
sion on HIV ART adherence. This practice of using mul-
tiple indicators safeguards against potential problems
with measurement error that can arise if a single imper-
fect indicator is used because measurement errors are
less likely to occur if several indicators are measured
[62,63].
Legal context of HIV: criminalization and prosecutions
The legal frameworks that facilitate prosecutions for
HIV exposure are rapidly changing throughout much of
the world. For clarity of discussion, we use the single
term laws to imply laws, regulations, and policies (in-
cluding legal precedent such as the basis for HIV-related
prosecutions in Canada). There are two types of laws
that influence the health of PLWH globally, protective
and punitive [13,16,29]. Protective laws include: (1)
those that protect people living with HIV against dis-
crimination; and (2) non-discrimination laws that specify
protections for vulnerable subgroups within a population
[29]. Punitive laws include: (1) HIV-specific restrictions
on entry, stay or residence; (2) specifically crim-
inalize HIV exposure or transmission; (3) criminalize
same-sex sexual activities between consenting adults; (4)
criminalize sex work (prostitution); (5) imposing com-
pulsory treatment for people who use drugs and/or pro-
vide for the death penalty for drug offences [13,29]; (6)
HIV-specific enhancements to sentencing for other
crimes [13]; (7) criminalize exposure to or transmission
of other diseases [13]; (8) requiring HIV disclosure [13];
and (9) requiring name-based HIV reporting [13]. Puni-
tive laws present obstacles for access to prevention,
treatment, care and support services for vulnerable
subpopulations.
The Legal Environment for People Living with HIV
(Table 1) was assessed by reviewing the relevant laws
and policies in the jurisdiction (either state/province or
national laws) that pertained to each study site. The
types of laws, regulations, or policies were organized
using eleven categories outlined by UNAIDS [29] and
Lazzarini, Bray, and Burris [13]. We limited our statis-
tical analysis to North American study sites and the fol-
lowing punitive legal categories: laws that specifically
criminalize HIV transmission or exposure; laws that
allow HIV-specific enhancements to sentencing for other
crimes; laws requiring HIV disclosure; laws requiring
HIV name-based reporting; and the total number of
HIV prosecutions in the jurisdiction where each study
site was located. We limited our analysis to these legal
categories, because these legal categories were consistent
across the majority of jurisdictions where study sites
were located. To facilitate data analysis, we characterized
the legal environment at each site by using one of three
codes for each type of law, regulation or policy–“yes”,
there is a law, regulation or policy; “no”, there is not a
law, regulation or policy; and “no data” are available
about laws, regulations or policies within the larger con-
textual environment where each study site was located.
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In an effort to quantify and better understand the
magnitude of criminalization of HIV exposure/transmis-
sion at each of our study sites, the total number of cu-
mulative HIV prosecutions was obtained for each
jurisdiction where this information was available. HIV-
related prosecutions are cumulative estimates from the
beginning of the epidemic in 1981 or when records of
HIV-related prosecutions became available within a geo-
graphic location. In the United States this information
was obtained from the Center for HIV Law and Policy
[27] Positive Justice Project and in Canada, this informa-
tion came from the Canadian HIV/AIDS Legal Network
[26] and the work of Mykhalovskiy and Betteridge [15].
Further legal contextual information for both countries
was obtained from United Nations General Assembly
Special Session (UNGASS) on HIV/AIDS country re-
ports [64] and the report Advancing HIV justice: A pro-
gress report on achievements and challenges in global
advocacy against HIV criminalisation published by the
Global Network of People Living with HIV (GNP+) and
the HIV Justice Network [65]. We made every effort to
obtain the most accurate information on HIV-related
prosecutions. However, the numbers represented here
are assumed not to constitute an exhaustive representa-
tion of all HIV-related prosecutions for the jurisdictions
where our study sites were located and is “likely only a
sampling of a much more widespread, but generally un-
documented, use of criminal laws against people living
with HIV” [27] p. 201. We did not obtain information
about HIV-related prosecutions or the effects of
criminalization of HIV exposure/transmission from our
study’s participants. Therefore, information reported
here only provides contextual information that may
highlight the potential challenges that HIV-related pros-
ecution and the criminalization of HIV exposure/trans-
mission may impose on PLWH at each study site.
Perceived social capital
Self-reported individual-level social capital was mea-
sured using 31-items, from the 36-item Social Capital
Scale [66-68]. This widely-used instrument measures
eight subscales including: participation in the local com-
munity, social agency, feelings of trust and safety, neigh-
borhood connections, friends and family connections,
tolerance of diversity, value of life, and workplace con-
nections; these items were used to create a total score.
In our analysis, the three workplace connections items
have been dropped, as well as two work-related ques-
tions that are part of the social agency dimension. This
was due to low anticipated employment status, because
Table 1 Legal contextual environment for people living with HIV
Law, Policy, Regulation Geographic Location of Study Site
Can USA PR
CA HI IL MA NJ NY NC OH TX WA
Protective
Laws and regulations/policies that protect people living with HIV against
discrimination
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Non-discrimination laws or regulations that specify protections for vulnerable
subpopulations
Yes NoThe Americans with Disabilities Act (ADA) excludes drug
users and sex workers.
Punitive
Laws, regulations or policies that present obstacles to access to prevention,
treatment, care and support for vulnerable subpopulations
Yes
Yes, for drug users and sex workers.
HIV-specific restrictions on entry, stay or residence No No* No* No* No* No* No* No* No* No* No* No*
Laws that specifically criminalize HIV transmission or exposure No Yes No Yes No Yes No Yes Yes No Yes No
Laws that criminalize same-sex sexual activities between consenting adults No No No No No No No No No No No No
Laws deeming commercial sex work to be illegal No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Laws that impose compulsory treatment for people who use drugs and/or
provide for death penalty for drug offences
No
Data
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Laws that allow HIV-specific enhancements to sentencing for other crimes No Yes No No No No Yes No Yes Yes Yes No
Laws that criminalize exposure/transmission to other diseases** No Yes No No No Yes Yes No No No Yes No
Laws requiring HIV disclosure Yes Yes No Yes No Yes No Yes Yes Yes Yes No
Laws requiring HIV reporting Yes No No No No Yes No Yes Yes Yes Yes No
Number of HIV prosecutions since 1981 13 10 0 18 4 4 4 4 25 22 8 0
Sample Size 100 300 100 95 200 100 100 200 150 228 200 100
Note: CA = California, Can = Canada, HI = Hawai’i, IL = Illinois, MA = Massachusetts, NC = North Carolina, NJ = New Jersey, NY = New York, OH = Ohio, PR = Puerto
Rico, TX = Texas, WA = Washington, UNK = unknown, *United States laws that restrict entry, stay or residence based on HIV-status were repealed in January, 2010;
**including communicable or contagious disease statutes that criminalize sexually transmitted infection exposure [27].
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employment rates among PLWH are considerably lower
than the general population in developed countries
[69,70]. Participants were asked to rate items on a 1–4
Likert-type scale. Higher mean scores indicate more so-
cial capital. Reliability and validity of the social capital
scale have been reported as acceptable [37,66].
Cronbach’s alpha reliability for the social capital scale for
our study was 0.88 and ranged from 0.84 to 0.93 for all
study sites.
HIV antiretroviral therapy adherence
For this study, HIV ART adherence was measured with a
visual analogue scale for 30-day adherence [71]. This
measure allows participants to self-report estimates of
their percentage of adherence during this period of time.
Participants were asked to mark how often they took
their medications in the past 30 days on a scale of 0% of
the time to 100% of the time [71]. This method is advan-
tageous because the data reported can be directly used
for analysis without calculating scores for analysis. This
30-day time frame for self-reporting medication adher-
ence was previously validated and overcomes the chal-
lenge of remembering specific doses missed [71-73].
Further, we dichotomized our participants’ self-reported
30-day adherence and those reporting 100% adherence
were categorized as adherent (coded with a value of 1)
and those who adhered at a lower level (< 99%) were
categorized as not adherent (coded with a value of 0).
This approach exceeds the 95% adherence threshold re-
quired for sustained HIV viral suppression [74-77].
Data analysis
All data were entered into a data management program
and sent to the coordinating center (UCSF) to check the
data integrity and assumptions for validity. Statistical
analyses were conducted using SPSS 20. An a priori sig-
nificance level of alpha = .05 was set to determine sig-
nificance for all statistical tests. Logistic regression was
used to assess the associations between HIV ART adher-
ence, criminalization of HIV exposure/transmission, and
perceived social capital. Measures to assess regression
model constructs were derived from demographic items
in the survey, the social capital scale [37,66], or data
obtained from publically available data sources about
laws affecting the health or social well-being of PLWH.
Perceived social capital scores used the mean social cap-
ital score derived from our survey data. The indicator
for HIV ART adherence (percentage adherent in the past
30-days) was used to derive a binary outcome variable
(100% adherence) and to assess associations between
each indicator for the legal context of HIV (e.g., prose-
cutions and laws), perceived social capital, and HIV ART
adherence.
Results
Sample surveyed and selected demographic
characteristics
Selected demographic characteristics for North Ameri-
can sites’ study participants (n = 1873) are summarized
in Table 2. Participants were primarily male (n = 1299;
69.4%) with an average age of approximately 46 years
(range 18–74 years). Most participants reported less
than adequate income (n = 1940; 89%), although 20%
(n = 367) reported that they were employed. Most par-
ticipants (n = 1500; 82%) were prescribed and currently
Table 2 Selected demographic and HIV disease
characteristics (n = 1873)
Frequency (%) Mean (SD)
Age (years) 46.1 (± 9.2)
Gender
Male 1299 (69.4)
Female 503 (26.9)
Transgender/Other 51 (2.8)
Ancestry (Race/Ethnicity)
African Am/Black 755 (40.3)
Latina/Latino 425 (22.7)
White 488 (26.1)
Other 179 (9.7)
Education
11th grade or less 491 (26.2)
High School 735 (39.2)
2+ yrs College 630 (33.9)
Income Adequate 495 (21.1)
HIV Disease Indicators
Year diagnosed with HIV 2,000 (± 6.6)
Prescribed HIV antiretroviral
therapy
1500 (82.3)
Has AIDS diagnosis 788 (42.1)
Undetectable Viral Load 1030 (58.1)
Frequency (%)
HIV transmission methoda Man Woman Transgender/
Other
Sex HIV+ man 791 (67.5) 396
(83.9)
42 (89.4)
Sex HIV+ woman 349 (33.3) 19 (4.8) 11 (36.7)
Sharing needles 301 (28.3) 122
(28.8)
17 (50)
Blood transfusion 76 (7.6) 41
(10.2)
6 (20.7)
Don’t know 124 (12.8) 34 (8.7) 4 (17.4)
Note. a Participants were asked to list the possible ways they could have been
infected with HIV. Responses were not mutually exclusive and participants
may have listed multiple modes of transmission. Transgender/Other includes
persons identifying as a transman, transwoman, genderqueer, other, or decline
to state.
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took HIV ART. More than half of the participants (n =
1030; 58.1%) self-reported an undetectable HIV viral
load. The majority of participants attributed their acqui-
sition of HIV to having sex with a man (n = 1239; 73%).
Of these, 64% (n = 791) were male, 32% (n = 396) were
female, and the remainder were transgender, other, or
declined to report their gender identity.
Legal context of HIV: criminalization and prosecutions
The legal context of HIV includes the laws, regulations,
policies, and legal precedents that influence the lives of
PLWH. The laws that contribute to HIV-related prose-
cutions and the numbers of persons being prosecuted
for HIV-related offenses vary widely across our study
sites (Table 1). Canada has no criminal legislation related
to HIV transmission or disclosure, but legal precedent
and Supreme Court of Canada decisions since 1998 have
resulted in more than 114 HIV-related prosecutions
[15,78]. The majority (approximately 69%) of HIV-
related prosecutions in Canada occurred after 2003 [15].
Many states in the United States have HIV-specific crim-
inal legislation (e.g., California, Illinois, New Jersey,
North Carolina, Ohio, and Washington). In the United
States, states and territories without HIV-specific laws,
regulations or policies may have established legal prece-
dent or other policy mechanisms through which PLWH
can be prosecuted or have their sentences enhanced
based on HIV status. For example, New York law does
not define whether criminal penalties apply to HIV ex-
posure, however courts there in at least two cases have
considered HIV a “deadly weapon” in assault cases [27].
Among jurisdictions where our study sites were lo-
cated, British Columbia has had 13 HIV-related prosecu-
tions and Canada has had the highest per capita rate of
HIV prosecutions among the two countries where our
study sites are located (n = 114) [15,28]. Additionally,
these prosecutions have increased dramatically since
2003 [15]. For comparison, in the United States there
have been 350 prosecutions for HIV-related crimes [27].
Among our study sites in the United States, Hawaii and
Puerto Rico currently have no punitive legal policies to-
ward PLWH and there have been no reported HIV-
related prosecutions in these jurisdictions. Among our
study sites, the states with the most HIV-related prose-
cutions were Ohio (n = 25) and Texas (n = 22). Three
jurisdictions where our study sites were located, Canada,
Illinois, and Ohio, are among the world’s top 30 jurisdic-
tions for HIV criminalization [65].
Perceived social capital
Among our North American study sites, we observed
moderately high levels of mean social capital scores ran-
ging from 2.53 ± 0.56 in California to 2.79 ± 0.55 in
North Carolina (possible scale range 1–4, higher values
signify greater perceived social capital). On average, par-
ticipants reported a mean social capital score of 2.63 ±
0.55. The mean social capital score for our Canadian
(2.54 ± 0.56) and California sites (2.53 ± 0.59) were low
in comparison to other North American sites. Per-
ceived mean social capital scores were highest in Hawai’i
(2.73 ± 0.56), Puerto Rico (2.74 ± 0.52), and North Caro-
lina (2.79 ± 0.55; Table 3).
HIV antiretroviral therapy adherence
Among our participants, the number of participants who
reported being prescribed HIV ART was high at 84.9%
(n = 1,590), range 78% in California to 91% in Hawai’i
and Puerto Rico. Self-reported HIV antiretroviral
Table 3 Social capital and HIV-antiretroviral adherence among people living with HIV
Site N Social Capital
μ (sd)
Adherence % past
30-day μ (sd)
Adherence
100%a n (%)
Prescribed HIV
antiretroviral therapy n (%)
Canada 100 2.54 (0.56) 84.1 (24.7) 37 (43.5) 85 (85)
Puerto Rico 100 2.74 (0.52) 88.7 (20.1) 51 (56) 91 (91)
California 300 2.53 (0.59) 82.7 (23.2) 86 (36.8) 234 (78)
Hawaii 100 2.73 (0.56) 89.6 (14) 32 (35.2) 91(91)
Illinois 95 2.66 (0.59) 83.4 (24.4) 29 (36.3) 80 (84)
Massachusetts 200 2.67 (0.54) 84.8 (23.2) 70 (40.7) 172 (86)
New Jersey 100 2.64 (0.48) 85.1 (21.9) 36 (43.4) 83 (83)
New York 100 2.69 (0.59) 83 (23.7) 31 (37.8) 82 (82)
North Carolina 200 2.79 (0.55) 86.1 (19.7) 78 (43.3) 180 (90)
Ohio 150 2.59 (0.52) 86.1 (20.9) 53 (41.4) 128 (85)
Texas 228 2.64 (0.52) 89.5 (19) 109 (55.6) 196 (86)
Washington 200 2.54 (0.56) 85.8 (23.8) 87 (51.8) 168 (84)
Total 1,873 2.63 (0.55) 85.7 (21.8) 699 (44) 1,590 (84.9)
Note. a = computed from 30-day adherence data; possible mean social capital scores range from 1 indicating poor social capital to 4 indicating high social capital.
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adherence was fair with mean 30-day adherence
reported at 85.7% of prescribed doses. Median 30-day
adherence was 95%. Fully, 52% (n = 827) of our partici-
pants were categorized as more than 95% adherent. The
level of adherence was highest among participants in
Texas (mean 30-day adherence, 89.5%; 60% [n = 118]
greater than 95% adherent) and lowest among partici-
pants in California (mean 30-day adherence, 82.7%;
45.7% [n = 107] greater than 95% adherent) and New
York (mean 30-day adherence, 83%; 39% [n = 32] greater
than 95% adherent). The largest percentage of partici-
pants who reported greater than 95% adherence was in
Washington 60.7% (n = 102; Table 3).
Correlation and logistic regression analyses
To determine if there were associations between the so-
cial structural factor of criminalization of HIV exposure/
transmission, perceived social capital, and HIV ART ad-
herence among an international sample of people living
with HIV, a correlation was computed (Table 4).
Spearman’s rho statistic was used to determine correla-
tions because two variables were skewed, past 30-day ad-
herence (skewness = −2.14) and number of HIV
prosecutions (skewness = 3.11). Mean perceived social
capital score, r (1588) = .168, p < .01; HIV disclosure re-
quired by law, r (1588) = .065, p = .01; and HIV expos-
ure/transmission is a crime, r (1588) = −.052, p = .04
were all significantly associated with 30-day adherence.
The positive association (r [1588] = .168, p < .01) be-
tween mean social capital score and 30-day adherence
means that PLWH who reported higher perceived social
capital also reported better average 30-day adherence.
The positive association (r [1588] = .065, p = .01) be-
tween HIV disclosure being required by law and 30-day
adherence means that PLWH who live in areas where
HIV disclosure is required by law reported better aver-
age 30-day adherence. PLWH who live in areas where
HIV exposure/transmission is a crime reported lower
30-day adherence as evidenced by a negative association
(r [1588] = −.052, p = .04; Table 4). Although signifi-
cantly associated, each of these three variables had a
weak association with 30-day adherence. Using r2 as an
indicator of effect size, 3% of the variance observed in
30-day adherence can be explained by perceived social
capital. The variables HIV disclosure is required by law
and HIV exposure/transmission is a crime each
explained less than 1% of the variance observed in 30-
day adherence.
Logistic regression was used to estimate the probability
of being 100% adherent in our sample of North American
adults living with HIV. Predictor variables were entered
into the statistical model based on our ecosocial theoretical
framework. Consistent with this framework, in the first
block, we entered the individual level demographic vari-
ables, gender, age, ancestry (race/ethnicity), education, and
years since HIV diagnosis. Next, the social network re-
sources variable of perceived social capital was added. In
the final block we added the HIV legal context variables,
number of HIV-related prosecutions, laws that specifically
criminalize HIV exposure or transmission, laws that allow
HIV-specific enhancements to sentencing for other crimes,
laws that criminalize exposure/transmission to other dis-
eases, laws requiring HIV disclosure, and laws requiring
HIV reporting. As shown in Table 5, individual level
demographic characteristics (block 1 likelihood ratio chi-
square = 44.44 [9] p < .001) and social network resources
(block 2 likelihood ratio chi-square = 25.35 [1] p < .001)
contributed statistically significantly to the overall model.
Table 4 Associations between criminalization of HIV, perceived social capital, and HIV antiretroviral adherence
Variable Correlations
30-day
adherence
100%
adherenta
Perceived
Social
Capital
HIV
Prosecutions
HIV Exposure/
Transmission
Law
HIV
Sentencing
Enhanced
Other Disease
Exposure/Transmission
Law
HIV
Disclosure
Law
100% adherenta .901**
Perceived Social
Capital
.168** .125**
HIV Prosecutions .006 .015 -.098**
HIV Exposure/
Transmission Law
-.052* -.038 -.050* -.161**
HIV Sentencing
Enhanced
.008 .027 -.099** .521** .225**
Other Disease
Exposure/Transmission
Law
-.049 -.025 -.086** -.064** .465** .518**
HIV Disclosure Law .065** .078* -.009 .394** .225** .144** -.145**
HIV Reporting Law .004 .022 -.072** .680** .678** .389** .217** .631**
Note: a = computed from 30-day adherence data, ** p < .01 (2-tailed), *p < .05 (2-tailed).
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The demographic characteristics that contributed the most
to adherence were age and ancestry (race/ethnicity). Older
participants were more likely to be adherent than younger
participants. Participants whose ancestry was Hispanic (La-
tino[a]) or White/Anglo were more likely to be adherent
than participants from any other ancestry category. His-
panics were twice as likely to be adherent and Whites were
2.4 times more likely to be adherent. The HIV legal context
variables entered in Block 3 did not statistically influence
the final model significantly (block likelihood ratio chi-
square = 10.66 [6] p = .093). However, the legal context
variable of HIV disclosure law did predict HIV ART adher-
ence among our participants. Persons in our sample who
lived in jurisdictions where HIV disclosure was required by
law were 1.4 times more likely to be adherent than those in
areas where HIV disclosure was not required by law
(p =.054). The logistic regression model successfully pre-
dicted HIV ART adherence with the overall model and 4
predictors (i.e., age, ancestry [race/ethnicity], perceived so-
cial capital, and HIV disclosure law) achieving statistical
significance and classification results indicated modest suc-
cess, with an overall correct classification of 60%. The over-
all effect size for the full model was also modest, with
Nagelkerke’s R2 equal to .072 [79,80]. Sensitivity analyses
using lesser degrees of HIV ART adherence (e.g., 80-95%)
were not statistically significant.
Discussion
The core constructs and intrinsic relationships of
ecosocial theory provide a means to better understand
structural factors that influence HIV antiretroviral ad-
herence, including criminalization of HIV exposure/
transmission. Embodiment is a multilevel phenomenon
that integrates soma, psyche, and society, within histor-
ical and ecological context [6] occurring through genea-
logical relationships that provides a clue to life histories,
both hidden and revealed [6]. Genealogical relationships
also shape pathways to embodiment in the ecosocial en-
vironment that involve “exposure, susceptibility, and re-
sistance (as both social and biological phenomena),
structured simultaneously by societal arrangements of
power… and constraint’s and possibilities of our biology”
[6], p. 225. Internal and economical, and external and
ecological intrinsic relationships shape accountability
and agency (who and what is responsible for social
inequities in health and for rectifying them) [6] among
members of society. From an ecosocial theory perspec-
tive, it is important to consider the influence of HIV
Table 5 Logistic regression summary for variables associated with HIV antiretroviral adherence (n = 1455)
95% CI, Odds ratio
Predictor B (SE) Wald Odds Ratio Lower Upper
Block 1: Individual Level Demographic Characteristics (X2 = 44.44, df = 9, p < .001)
Gender -.156 (.096) 2.642 .855 .708 1.033
Age .016 (.007) 5.453* 1.016 1.003 1.030
Ancestrya 30.577**
Asian/Pacific Islander (n = 39) .055 (.472) .013 1.056 .419 2.663
African American/black (n = 581) .153 (.335) .207 1.165 .604 2.248
Hispanic/Latino(a) (n = 343) .722 (.349) 4.270* 2.058 1.038 4.080
Native American Indian (n = 47) .060 (.460) .017 1.061 .431 2.616
White/anglo (non-Hispanic) (n = 398) .859 (.337) 6.498* 2.361 1.220 4.570
Education -.033 (.054) .364 .968 .870 1.077
Year diagnosed with HIV .011 (.008) 1.750 1.011 .995 1.027
Block 2: Social Network Resources (X2 = 25.35, df = 1, p < .001)
Perceived Social Capital .517 (.104) 24.834** 1.676 1.368 2.054
Block 3: HIV Legal Context (X2 = 10.66, df = 6, p = .093)
HIV Prosecutions -.003 (.004) .418 .997 .989 1.006
HIV Exposure/Transmission Law -.176 (.257) .469 .838 .506 1.388
HIV Sentencing Enhanced -.005 (.149) .001 .995 .742 1.334
Other Disease Exposure/Transmission Law .118 (.160) .543 1.125 .823 1.538
HIV Disclosure Law .321 (.166) 3.726* 1.379 .995 1.911
HIV Reporting Law .200 (.322) .385 1.221 .650 2.295
Constant, overall model −24.500 (16.569) 2.186
Note: Model X2 = 80.66, df = 16, p < .001); Nagelkerke R2 = .072; percent correctly classified = 60%; parameter values reported are from the final logistic regression
model; areference category for ancestry is other (n = 47); * p ≤ .05; ** = p < .01.
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criminal laws and social capital on HIV antiretroviral ad-
herence from multiple levels (e.g., individual, neighbor-
hood, political jurisdiction, national) and in multiple
domains (e.g., home, work, other public settings). This
study’s participants represent many of the most vulner-
able members of North American society.
HIV antiretroviral therapy adherence
Our analysis of the ecosocial factors influencing HIV ART
adherence in North America identified significant positive
associations between perceived social capital, HIV disclos-
ure required by law, and self-reported HIVART adherence.
However, it is worth noting that there is no gold standard
of HIVART adherence measurement. All measures of HIV
ART adherence have limitations [71,74,81,82]. Medication
event monitoring system (MEMS) use is difficult to imple-
ment because of high cost and patient resistance/lack of
cooperation and difficulty to monitor MEMS devices and
data retrieval when study visits are as long as 6 months
apart. Pill counts, pharmacy refill data, and therapeutic
plasma drug monitoring all have drawbacks that limit their
utility. Considering these factors and the inter-correlations
among these measurement approaches [82,83], we used
two well-validated adherence measures. The visual analog
scale (VAS) developed by Walsh [71,84] that assesses 30-
day adherence reporting separately for each drug along a
continuum anchored by “none of my doses” to “every one
of my doses.” This measure has shown to be correlated
with other measures of adherence, such as MEMS [71,85]
and a 30-day timeframe has recently been supported as
preferable to other approaches of self-report [73]. We also
used a 30-day adherence rating scale that has been
recommended by Lu and colleagues [73], in which partici-
pants are asked “Thinking back over the past 30 days, rate
your ability to take all your medications as prescribed”
(6 response ratings: Very poor, Poor, Fair, Good, Very good,
and Excellent). This approach has yielded the least over-
reporting when compared to MEMS. These approaches,
however, are still susceptible to reporting biases and likely
suggest an overestimate of actual adherence. Conserva-
tively, we chose to dichotomize at perfect vs. less than per-
fect adherence; finer gradations in the self-reported
adherence data (e.g., 90%, 80%) are questionable given the
nature of the instrument and the imprecision of recall and
reporting of medication-taking behavior.
Our statistical analyses were only sensitive to the most
stringent rates of HIV ART adherence (i.e. 100% adherence).
This finding leads us to believe that longitudinal research
that explore our model constructs is needed to more fully
understand how HIV-related criminal prosecutions and per-
ceived social capital influence HIV ART adherence among
persons living with HIV in North America. Future studies
should include both longitudinal and multi-site study de-
signs that specifically inquire about PLWH’s encounters
with the criminal justice system in addition to measuring
their perceptions of social capital and HIV ART adherence.
In addition to quantitative studies, there needs to be qualita-
tive research that explores at the individual level the influ-
ence that HIV-related criminal law approaches have on the
lives of PLWHs and how they navigate their experiences
with stigma and discrimination that these laws perpetuate.
Many factors that influence a person’s HIV antiretro-
viral adherence have been documented, including indi-
vidual factors (e.g., anxiety, depression, illicit drug use,
knowledge about disease and medication regimen),
interpersonal factors (e.g., social support, effective
patient-provider relationships), and social/structural fac-
tors (e.g., homelessness, access to care and treatment).
Among our study’s participants, evidence of the influ-
ence of anxiety and depression on HIV antiretroviral ad-
herence has been documented [86]. Support for
adherence self-efficacy predicted adherence behavior,
among our participants and may partially mediate envir-
onmental influences and cognitive or personal factors
[59]. Additionally, factors that mediate HIV antiretroviral
adherence among participants include sense of coher-
ence (“overall well-being and ability to cope with stress”
[86]), self-compassion, and engagement in care [58]. The
information from these studies highlights the effects of
individual and interpersonal level factors that influence
adherence among our participants and suggest that add-
itional structural factors may also influence adherence.
The criminalization of HIV exposure/transmission may
not be the only structural level factor that influences ad-
herence among our study participants. Homelessness
and access to care and treatment may also influence ad-
herence among our study’s participants, however we do
not have data to support these conclusions.
Criminalization of HIV exposure/transmission and HIV-
related prosecutions
HIV antiretroviral adherence is an essential component
of managing HIV at both individual and population
levels. Our study’s use of ecosocial theory, allows us to
better understand the internal and economical and ex-
ternal and ecological intrinsic relationships and the cu-
mulative interplay among exposure, susceptibility, and
resistance that influence HIV antiretroviral adherence as
part of the embodied social ecology for our study’s par-
ticipants. Our findings related to adherence among
PLWH who live in jurisdictions were the potential for
HIV-related prosecutions exist underscore the complex
social dynamics at play in the discourse about the use of
criminal law to manage HIV disease. The challenge of
balancing individual rights to freedom of sexual expres-
sion and the protection of the health of a population are
at odds here. Criminalization of HIV exposure/transmis-
sion as a prevention intervention has limited efficacy
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[9-11,14,17] and does not provide sufficient protection
for persons who engage in high risk sexual behavior,
who may assume they are protected because there is a
law to protect them. The continued practice of prosecut-
ing persons for HIV-related “crimes” may actually limit
the effectiveness of other HIV prevention interventions.
There is also evidence that continued HIV-related prose-
cutions may reduce the likelihood that persons who
know their HIV status will seek treatment [87]. Human
rights based HIV prevention interventions may allow us
to capitalize on altruistic behaviors exhibited by PLWH
[14,17].
The teleological intrinsic relationship described by
Krieger [7] and our findings of associations between the
legal context of HIV and ART adherence may be evi-
dence of the existence of the concept of “therapeutic
citizenship” in North America. This concept has been
used to characterize rates of adherence to ART among
PLWH in developing nations [88]. The concept is based
on the view that citizenship is “enacted through a web of
institutional and political cultures, rather than the more
classic understanding of the political relationship be-
tween citizen and state” [88] p. 34. Nguyen et al. [88]
used the concept of therapeutic citizenship to under-
stand exemplary adherence observed in societies whose
governments have severely limited economic resources
for the provision of health care and social services. In
these societies, PLWH are challenged with retaining fa-
milial and social networks while navigating and
accessing health care and social service resources from
governmental agencies. They described environments
where PLWH appropriate ART as a set of rights and
responsibilities that facilitate their negotiation of
conflicting moral economies in their fight to manage
HIV and remain viable members of society [88].
We contend that the concept of therapeutic citizen-
ship among PLWH is applicable in Canada and the
United States because the potential for prosecution for
HIV nondisclosure, exposure, or transmission creates
conflict between the individual and society. Our findings
of higher rates of adherence in geographic locations
where prosecutions for HIV occur may be partially
explained by a desire among PLWH to be “good thera-
peutic citizens” and protect others from exposure to
HIV [14]. An alternate explanation for this finding may
be that PLWH fear being accused of not being a good
therapeutic citizen and facing the potential for HIV-
related prosecution [17]. Through the practice of adher-
ence to HIV antiretroviral medications, PLWH reduce
the likelihood of exposing others to HIV. We suspect
that our observation of increased adherence to HIV ART
in jurisdictions where HIV disclosure is a legal require-
ment is partially explained by “therapeutic citizenship”
being enacted by our participants and an example of
their ethical commitment to protect others from expos-
ure to HIV [14].
From a public health perspective, it is disconcerting that
HIV-related prosecutions and the criminalization of HIV
exposure/transmission continues. HIV is currently the only
disease for which people can be prosecuted even if they do
not transmit the virus to another person. The
criminalization of HIV exposure/transmission as a struc-
tural HIV prevention intervention may create a “catch 22”
scenario for PLWH. PLWH who work to achieve optimal
health and engage in practices to be a good therapeutic
citizen by adhering to HIV ART may lose hope for living a
normal life in a society that does not accept them as hu-
man beings. The continued practice of HIV-related prose-
cutions and criminalization of HIV exposure/transmission
contributes to the creation of a viral underclass [89] that
faces stigma and discrimination with the threat of prosecu-
tion and incarceration [17].
Perceived social capital
The intrinsic relationships within ecosocial theory most
relevant to understanding perceived social capital in our
study are internal and economical and external and eco-
logical relationships. Our findings related to perceived so-
cial capital highlight the importance of social networks and
the collective ability of PLWH to navigate the challenges
they face in their daily lives. Perhaps this is because our
study participants hold similar socioeconomic position
within their respective geographic locations. This leads us
to believe that the importance of social capital and the
“credits” it offers individual members of a society may be
essential elements in the global fight to end the HIV epi-
demic. In addition, our findings related to perceived social
capital reinforce the importance of the concept of thera-
peutic citizenship as a collective benefit to PLWH and all
members of societies where they live.
Limitations
Our study was influenced by an overrepresentation of
factors that are relevant to contexts within the United
States because of the large number of surveys collected
within the United States. This limitation reduces the
ability to generalize findings outside the United States,
because there may be insufficient power to determine
statistical differences for our Canadian site. The non-
random recruitment strategy used may introduce bias,
which may be especially evident in the level of perceived
social capital, because persons participating may have
sufficient social capital to gain access to the health care
resources they need, including participation in research
studies. Our reliance on ART adherence self-report sur-
vey data and lack of biological markers to assess adher-
ence may have resulted in biased data. In the absence of
an affordable and non-invasive adherence measure [90],
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we believe that reliance on the 30-day self-report visual
analogue scale used provided valid and sufficient ART
adherence information to determine the effects of struc-
tural factors influencing ART adherence. Additionally,
our study’s survey responses may be influenced by social
desirability bias.
Additional limitations indicative of the complexity of
studying structural challenges influencing HIV include the
challenge of obtaining accurate and current legal and pol-
icy information related to the criminalization of HIV and
how ancestry (race/ethnic) data were collected. Our use of
the United States’ Census Bureau ancestry (race/ethnic)
categories complicates interpretation of data from our
Canadian study site [51]. Use of this classification system
may be insufficient to accurately represent epidemic trends
in Canada and the United States. Our study findings pro-
vide limited evidence about the effects of HIV-related
criminal laws and social capital on HIV ART adherence
among women, transgender, and other minority groups.
Thereby limiting our ability to understand the effect of
HIV-related criminal laws on the HIV ART adherence be-
haviors of women, transgender, and other minority mem-
bers of society.
Conclusions
In this study, we observed weak but significant associations
between the structural factor of criminalization of HIV ex-
posure/transmission and its association with HIV ART ad-
herence. This observation was associated with the
individuals’ perceived social capital. Our finding of associa-
tions between HIVART adherence and indicators from the
structural level of criminalization of HIV exposure/trans-
mission and the individual’s perceived social capital provide
evidence to help better understand the ecosocial context of
HIV and its’ influence on health promoting behavior
among PLWH. These findings highlight the importance of
addressing not only biomedical issues, but the social and
structural challenges that influence health behavior among
PLWH. In both our correlation and regression analyses,
perceived social capital consistently emerged as an indica-
tor associated with HIV ART adherence. This observation
underscores the importance of considering social capital in
the effective management of HIV disease globally. Current
biomedical approaches to HIV offer the technological ad-
vantage of controlling HIV at the molecular and cellular
levels [91]. These advantages however, will have limited
benefit without also addressing the social and structural
challenges that allow HIV to continue to spread among so-
cieties’ most vulnerable and at risk populations. Overcom-
ing these challenges requires intersectoral cooperation
and the political will to implement evidence-informed
health policies and legal reforms aimed at achieving opti-
mal health and wellness for all.
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